Israel’s second largest healthcare provider and a world leader in digital health services. Maccabi Healthcare currently operates in 500 facilities with 12,000 employees, 2 million members and access to 6,400 MDs and 800 DMDs. Offering “birth-to-death” healthcare in a digital environment making their big data opportunity second to none.
One of the world’s leading health providers with 6.2M patient visits, 44,430 caregivers, 27 institutes with 120 sub-specialties and one of the top 5 hospitals in the world. Cleveland Clinic Innovations has filed more than 2,850 patent applications, 450 royalty licenses, completed 75 spin-offs, and contributed $833M in follow-on equity investments.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen is the largest independent biotechnology company in the world, with presence in over 100 countries and approximately 20,00 employees.
The company was founded in 1980 and focuses on the development of therapeutics in a variety of areas (oncology, hematology, cardiovascular, neurology and others).
Traded on NASDAQ (AMGN) at a market cap of approx. $120B, 2014 revenues were over $20B and the R&D expenditure was over $4B.
Medison, the largest Israeli independent specialty pharma company, is representing multiple global leading biopharma companies in Israel. Medison is also an active player in the innovative and vibrant biotech arena in Israel, uniquely bridging between its partners and the local ecosystem.
Founded in 2006, SCI (Shanghai Creation Investment) Ltd. in Shanghai, China (SCI) is one of the most active investment funds and consulting companies in China. Over the past 10 years, SCI successfully made investments in medical domains and other sectors. SCI provided well recognized consulting services for enterprises at different stages and under different scenarios. SCI has made extensive research in many fast growing industries, including advanced equipment, automobile, consumer goods, medical devices, and advanced materials. By June 2015, SCI has successfully helped approx. 30 China and USA enterprises in private financing, M&A, or public listing. The amount of private equity financing is totaled at more than USD 500 Million. The main areas of investments are health care, high-end manufacturing, and new materials.